Nano cap Soligenix (NASDAQ:SNGX) rockets 89% premarket on robust volume in reaction to its license deal with Boston Scientific (NYSE:BSX)
unit BTG Specialty Pharmaceuticals for exclusive global rights to
CoVaccine HT, a novel vaccine adjuvant, for use in a COVID-19 vaccine.
An adjuvant is designed to boost the immune response, thereby enhancing the effects of a vaccine.
Financial terms are not disclosed.
https://seekingalpha.com/news/3561207-soligenix-up-89-premarket-on-deal-for-covidminus-19-vaccine-adjuvant
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.